FGFR3 and Alzheimer disease: Our study demonstrates that (1) cholinergic circuit Cho and NAA can be used as biomarkers for early AD and (2) chemical genetics-driven Ach cycle activities of the cholinergic circuit attenuate early memory impairment in APP/PS1 mice.